Press Release

Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson’s Disease

Truvian Health Presents Multi-Site Clinical Study Data on Its Benchtop Blood Testing Platform to Enable Central Laboratory Quality Results Anywhere

Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona

SonoThera™ Expands Leadership Team Appointing Carolyne Zimmermann as Chief Business Officer

Dr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions

ProJenX Announces Formation of Scientific Advisory Board

AVILAR THERAPEUTICS INCREASES FINANCING TO $75 MILLION TO ADVANCE PIPELINE OF NOVEL EXTRACELLULAR PROTEIN DEGRADERS

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank

Multi-omics Startup Pleno Inc. Continues to Strengthen its Board of Directors